Santander's Profit Beats Expectations on Lower Provisions, Costs

Spain’s largest bank by market capitalization reported a 12% on-year increase in net profit for the three months ended Sept. 30, as lighter provisions and costs helped offset the impact from the lower interest-rate environment.

Topics

JD Sports Expects Profit at Lower End of Guidance
Business - The Wall Street Journal - 7 hours ago
Average cost of Thanksgiving dinner is expected to be lower than past years
Top stories - CBS News - 54 minutes ago
Wall Street is lowering expectations for corporate profits in 2025. Should investors be concerned?
Business - MarketWatch - Yesterday
Hasbro’s third-quarter profit beats expectations, but its stock slips
Business - MarketWatch - October 24
Samsung Sees Progress in Memory Chips for AI After Delays
Tech - The Wall Street Journal - October 31
Honeywell’s stock falls as sales miss and lowered guidance offsets profit beat
Business - MarketWatch - October 24
Santander sets aside £295mn to cover costs over car finance ruling
World - Financial Times - 22 hours ago
Deutsche Bank shares shed 3% as lender's swing back to profit fails to impress
Business - CNBC - October 23

Santander's Profit Beats Expectations on Lower Provisions, Costs

Topics

Related

JD Sports Expects Profit at Lower End of Guidance

Average cost of Thanksgiving dinner is expected to be lower than past years

Wall Street is lowering expectations for corporate profits in 2025. Should investors be concerned?

Hasbro’s third-quarter profit beats expectations, but its stock slips

Samsung Sees Progress in Memory Chips for AI After Delays

Honeywell’s stock falls as sales miss and lowered guidance offsets profit beat

Santander sets aside £295mn to cover costs over car finance ruling

Deutsche Bank shares shed 3% as lender's swing back to profit fails to impress

More from The Wall Street Journal

Boohoo Changes Chairman as Frasers Calls For Removal

Resolute Mining Says CEO, Employees Released From Detention in Mali

JD Sports Expects Profit at Lower End of Guidance

Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio

Julius Baer Assets Rise as Inflows Accelerate